CARMIEL, Israel--(BUSINESS WIRE)--Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX), announced today that Frost & Sullivan has presented the Company with its 2009 European Orphan Diseases Market Product Innovation of the Year Award. In presenting the award, Frost & Sullivan noted the Company’s impressive display of technology and innovative efforts in developing prGCD, the Company’s proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) for the treatment of Gaucher disease using its proprietary expression system, ProCellEx™.
